These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 29902067)

  • 1. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP; Selinger CI; Mahar A; Cooper WA
    Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
    Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive markers in lung cancer: a few hints for the practicing pathologist.
    Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
    Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
    Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
    Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
    J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of ALK and ROS1 rearrangements by immunocytochemistry on cytological samples].
    Frankel D; Bourlard D; Garcia S; Robaglia-Schlupp A; Peker E; Groliere A; Kaspi E; Roll P
    Ann Pathol; 2019 Jun; 39(3):227-236. PubMed ID: 30709602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
    Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnosis in non-small-cell lung cancer: expert opinion on
    Conde E; Rojo F; Gómez J; Enguita AB; Abdulkader I; González A; Lozano D; Mancheño N; Salas C; Salido M; Salido-Ruiz E; de Álava E
    J Clin Pathol; 2022 Mar; 75(3):145-153. PubMed ID: 33875457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
    Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
    Remon J; Pignataro D; Novello S; Passiglia F
    Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples.
    Frankel D; Kaspi E; Roll P
    Methods Mol Biol; 2021; 2279():157-164. PubMed ID: 33683692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
    Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
    J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
    Singh A; Kumar R; Shetty O; Desai S; Rane S
    Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.